HealthMore in Health→
FDA Oncology Advisers Reject AstraZeneca’s Trial Framing in Breast Cancer Review
Key Takeaways
- FDA oncology advisers voted 6-3 against the clinical meaningfulness of AstraZeneca’s trial results.
- The panel pushed back on what was described as a proposed new paradigm.
- The vote signals regulatory skepticism, though it does not by itself determine final FDA action.
DE
DT Editorial Team··via endpoints.news